Loading clinical trials...
Loading clinical trials...
A subset of heavy marijuana users have trouble quitting marijuana use and the number of those seeking treatment for problems related to marijuana is increasing. The purpose of this research study is to investigate whether dronabinol can reduce withdrawal effects associated with stopping marijuana use, if dronabinol can reduce the rewarding effects of smoked marijuana, and whether there are any cognitive performance deficits associated with dronabinol doses that produce such effects.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
Yes
Behavioral Pharmacology Research Unit
Baltimore, Maryland, United States
Start Date
April 1, 2009
Primary Completion Date
October 1, 2011
Completion Date
October 1, 2011
Last Updated
August 3, 2017
24
ACTUAL participants
Dronabinol 30mg/day
DRUG
Dronabinol 60mg/day
DRUG
Dronabinol 120mg/day
DRUG
Placebo
DRUG
Lead Sponsor
Johns Hopkins University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT03717272